Interview with Cornelia Yzer , CEO, VFA
2007 was a turning point for the German Pharmaceutical Industry as the Healthcare Reform from 2007 took place and the Special SHI enhancement Act entered into force. Two years down…
Address: Friedrichstraße 60,10117 Berlin ,Germany
Tel: +49 (0)30 200 099-0
Web: http://www.vfa.de/
The VFA – the Association of Research-Based Pharmaceutical Companies (vfa) – is the trade organization of research-based pharmaceutical companies in Germany. 48 leading research-based pharmaceutical companies are organized in the vfa. Together with their more than 100 subsidiaries and affiliated companies, they employ nearly 90,000 people in Germany.The vfa members represent more than two-thirds of the entire German pharmaceutical market. The vfa member companies are among the leading research-based pharmaceutical companies worldwide. They guarantee therapeutic progress in pharmaceuticals and ensure high-quality pharmaceutical therapy.
2007 was a turning point for the German Pharmaceutical Industry as the Healthcare Reform from 2007 took place and the Special SHI enhancement Act entered into force. Two years down…
The latest from German pharma, including Bayer’s 2021 financial results, the country’s plan to spend $3.14 billion on vaccine capacity to cover Covid-19 outbreaks until 2029, and Boehringer Ingleheim’s case…
A roundup of the latest news from European biotech, including BioNTech and CureVac’s German vaccine manufacturing deal; the revival of Valneva’s plans to manufacture its vaccine in Scotland; and Morphosys’…
At the recent FT webinar, ‘Supporting Pharma Innovation in Europe’, high-level representatives from Roche, Bayer, and the European Commission weighed in on how European pharma’s competitive position on innovation is…
Building on points developed in his 2020 PharmaBoardroom interview, Professor Nicolaus Kröger of the European Society for Blood and Marrow Transplantation (EBMT) outlines the progress made by the multi-stakeholder GoCART…
In the wake of the 2021 United Nations Climate Change Conference (COP26), sustainability is once more a hot-button issue across all industries, including pharma. Here, Marco Rauland, vice president global…
Christian Conrad outlines his role as patient engagement lead for Novartis Oncology in Germany, how individual patient interactions differ from those with advocacy groups, and the current situation for cancer…
After a challenging 2020, and with more hurdles in sight, Bayer has been on an investment spree with a USD 2 billion acquisition of a San Diego-based biotech and manufacturing…
The latest news from German pharma, including Bayer’s USD 2 billion acquisition of San Diego’s Vividion Therapeutics; Boehringer Ingelheim’s new investment in a Vienna production facility; BioNTech’s plans to inaugurate…
The Top Five countries in Europe ranked by amount spent on pharma R&D. While some of the continent’s largest and most developed nations are represented, other smaller countries are punching…
Writing in the August edition of DIA’s Global Forum, Sanofi R&D’s Thomas Kühler outlines the bumpy journey towards the full adoption of Health Technology Assessment (HTA) across Europe. More…
Boehringer Ingelheim’s Hubertus von Baumbach, the newly appointed president of the European Federation of Pharmaceutical Industries and Associations (EFPIA), shares the goals of his presidency and the role of the…
The latest news from German pharma, including a new US leadership team and more COVID-related investment at Merck KGaA; the CureVac vaccine’s role in fighting COVID-19 variants; and why the…
See our Cookie Privacy Policy Here
